Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTS167 in Advanced Hematologic Malignancies
NCT02795520Phase 2Terminated
- Sponsor
- OncoTherapy Science, Inc.
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OTS167 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more, sponsored by OncoTherapy Science, Inc. Primary endpoint: Adverse events assessed by CTCAE v4.03. Started Apr 2016; status: terminated.
02
Drugs
OTS167
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02795520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795520.